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Abstract
Background: The aim of this study was to analyse the genetic patterns of Hemagglutinin (HA) genes of influenza A strains
circulating on Corsica Island during the 2006–2009 epidemic seasons and the 2009–2010 pandemic season.
Methods: Nasopharyngeal samples from 371 patients with influenza-like illness (ILI) were collected by General Practitioners
(GPs) of the Sentinelles Network through a randomised selection routine.
Results: Phylogenetic analysis of HA revealed that A/H3N2 strains circulating on Corsica were closely related to the WHO
recommended vaccine strains in each analyzed season (2006–2007 to 2008–2009). Seasonal Corsican influenza A/H1N1
isolated during the 2007–2008 season had drifted towards the A/Brisbane/59/2007 lineage, the A/H1N1 vaccine strain for
the 2008–2009 season. The A/H1N1 2009 (A/H1N1pdm) strains isolated on Corsica Island were characterized by the S220T
mutation specific to clade 7 isolates. It should be noted that Corsican isolates formed a separate sub-clade of clade 7 as a
consequence of the presence of the fixed substitution D222E. The percentages of the perfect match vaccine efficacy,
estimated by using the pepitope model, against influenza viruses circulating on Corsica Island varied substantially across the
four seasons analyzed, and tend to be highest for A/H1N1 compared with A/H3N2 vaccines, suggesting that cross-immunity
seems to be stronger for the H1 HA gene.
Conclusion: The molecular analysis of the HA gene of influenza viruses that circulated on Corsica Island between 2006–2010
showed for each season the presence of a dominant lineage characterized by at least one fixed mutation. The A/H3N2 and
A/H1N1pdm isolates were characterized by multiples fixation at antigenic sites. The fixation of specific mutations at each
outbreak could be explained by the combination of a neutral phenomenon and a founder effect, favoring the presence of a
dominant lineage in a closed environment such as Corsica Island.
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Introduction
Type A influenza viruses are major pathogens for humans.
Influenza A virus is further classified based on the antigenic
properties of its surface glycoproteins, the Haemagglutinin (HA)
and the Neuraminidase (NA) [1]. Influenza A/H3N2 and A/
H1N1 subtypes are the major subtypes currently circulating in
human populations [2]. HA is of special interest due to its role in
the viral entry mechanism and immune recognition. It consists
of two subunits: HA1, which contains the receptor-binding and
antigenic domains, and the HA2 subunit, which is responsible for
the fusion of the virion with the endosomal membrane of the host
cell [3]. The HA1 subunit undergoes a process termed positive
Darwinian selection through continuous antigenic mutations that
allow the virus to evade the host’s humoral immune response [4].
This process is called antigenic drift. Variants that best escape
the host immune response are thought to have a significant
reproductive advantage [5]. Specifically, the variable antigenic
regions of the HA1 domain are potential targets of neutralising
antibodies, and thus amino acid substitutions at these regions (A to
E) have been associated with annual epidemics in humans. In
contrast, the amino acids within the receptor binding site (RBD) of
the HA1 domain are relatively conserved. Variations have also
been observed in the N-linked glycosylation sites of HA, with some
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4strains having lost or gained a glycosylation site and potentially an
altered glycoprotein function. Concerning the NA, antigenic
variations usually occur in the catalytic or framework sites of the
protein.
Another process, called reassortment, is also considered to be a
major force in the evolution of influenza virus [5]. It occurs when
the virus acquires an HA of a different influenza virus subtype via
reassortment of one or more gene segments, and this is thought to
be the basis for the more devastating influenza pandemics [6].
New influenza pandemics may emerge through reassortment with
strains from swine or avian reservoirs [7].
The first influenza pandemic of this century was declared in
April of 2009, with the emergence of a novel H1N1 influenza A
virus strain in Mexico and the USA [8,9]. In France, the A/
(H1N1)2009 pandemic wave spanned from September 6, 2009 to
December 26, 2009 (www.sentiweb.fr ). During the epidemic, the
pandemic strain was almost exclusively found among influenza
virus isolates [10].
The effectiveness of annual influenza vaccines depends on the
selection of component strains that offer optimal immunity from
the numerous variants in the global influenza virus circulation.
Studies based on sequencing analyses of viruses can be utilised as
surveillance tools and can contribute to the vaccine selection
process when they are combined with classical serological
antigenic analysis.
The aim of this study was to analyse the genetic patterns of HA
genes of influenza A strains circulating on Corsica Island during
the 2006–2009 epidemic seasons and the 2009–2010 pandemic
season.
Methods
Ethics Statement
Based on French national laws ethical permissions (Law 1121-
1- 1u R. 1121- 2) are not required for specific microbiological
diagnostics treatment of the patients and further characterization
of the viruses. All samples were coded and tested anonymously.
Patient information was stored according to national regulations
and access to such data was restricted (permissions CNIL 471393).
Clinical samples and epidemic data
Three hundred and seventy one samples from patients with
influenza-like illness (ILI) were collected by Sentinelles General
Practitioners (GPs) of the Sentinelles Network starting with the
2006–2007 season (Fig. 1). All cases represented mild infections.
Nasopharyngeal swabs and clinical data were collected through a
randomised selection routine. Doctors included the first patient of
each week, of any age. Corsican Sentinelles GPs swabbed patients
presenting an ILI according to the Sentinelles definition: ‘‘sudden
onset of fever .39uC( .102uF) with respiratory signs and
myalgia’’ [11].
The nasopharyngeal swabs were sent by mail in 2 ml of viral
transport medium within two days to the virological laboratory.
Detailed demographic and clinical data (the time of onset of
symptoms, reported symptoms, physical findings and influenza
vaccination status) were obtained from patients during the medical
visit.
RT-PCR Assays for Influenza Virus Detection and
Subtyping
After processing the clinical materials by the standard
laboratory procedures, the individual sample was inoculated in
the Madin Canine Kidney (MDCK) cell lines for the isolation of
viruses. The inoculated MDCK cell line was observed at 34uC for
cytopathic effects. The viruses were passaged three times to obtain
sufficient virus titers for virus identification.
RNA was extracted from 140 ml of clinical sample and of the
supernatant using the QIAmp Viral RNA Mini kitH (QIAGEN,
Courtaboeuf, France). Multiplex RT-PCR assays were performed
using the One-step RT-PCR kitH (QIAGEN, Courtaboeuf,
France) and using primers based on the M, HA and NA
glycoprotein gene sequences of seasonal influenza A/H1N1 and
A/H3N2 viruses [12–14]. Positive and negative controls were
included in each multiplex RT-PCR.
In order to detect and assign the A/H1N1pdm strains isolated
from patients, a real-time PCR assay was performed using a
specified RT-PCR protocol provided by the French National
Influenza Centre [15]. Positive and negative controls were
included in each RT-PCR run.
For the detection of A/H1N1pdm, the M RT-PCR was
associated with a specific RT-PCR targeting the HA gene. This
strategy is pertinent in the context of a pandemic as the new virus
may drift, mainly due to mutation in hemagglutinin and/or
neuraminidase genes, but variants will still be detected by this
universal M RT-PCR [15].
Nucleotide sequencing
The HA sequences were amplified using the primer set for A/
H1N1, A/H1N1pdm and A/H3N2 influenza virus (primers
sequences are available on request). The resulting amplicons were
analyzed by 2% agarose gel electrophoresis. Double-stranded
sequencing of the purified PCR products was performed using an
Applied Biosystems Sequencer (ABI 3700 Perkin- Elmer).
Nucleotide sequence accession numbers
The nucleotide sequence data from this study were deposited
with the following accession numbers: for A/H1N1 isolates
between JF701798 and JF701831; for A/H3N2 isolates between
JF701832 and JF711877 and for A/H1N1pdm isolates between
JF01878 and JF701906.
Phylogenetic analysis
Nucleotide sequences were aligned with the CLUSTAL X [16]
program for the major coding regions of the three segments: HA
(875 bp) for A/H3N2 isolates from 2007–2008 and 2008–2009,
HA (1056 bp) for A/H1N1 isolates from 2006–2007 and 2007–
2008 and HA (1018 bp) for A/H1N1pdm from 2009–2010. The
Find Model program [17] was used to identify the optimal
evolutionary model that best fitted our sequence dataset. Akaike
Information Criteria and the hierarchical likelihood ratio test
indicated that the HKY+C model was the best fit to the data. To
infer the evolutionary relationship for the influenza virus analyzed,
we employed the Maximum likelihood (ML) trees constructed
under the HKY+C model using software from the PhyML
program [18].
The genomic sequences of the vaccine strains and the other
strains used in this study were obtained from the Influenza
Sequences Database (http://www.flu.lanl.gov).
Nucleotide diversity
The average pairwise nucleotide diversity among sequences was
estimated for the A/H3N2, the A/H1N1 seasonal influenza
viruses and for the A/H1N1 pdm virus population. For this
analysis, a maximum likelihood (ML) method was employed,
available in the MEGA4 package [19], with the standard deviation
estimated using 100 bootstrap replicates.
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PotentialN-glycosylationsites(aminoacidsAsn-X-Ser/Thr,where
X is not Asp or Pro) were predicted using nine artificial neural
networks with the NetNGlyc server 1.0 [20]. A threshold value of 0.5
average potential score was set to predict glycosylated sites.
Estimation of vaccine efficacy (VE) using the pepitope
model
Antigenic distance is a quantity that should define difference of
viral strains, as determined by the human immune system. The
pepitope sequence-based method has been shown to be an effective
antigenic distance measure between two influenza viral strains
[21–24]. The meta-analysis of epidemiological human VE studies
shows that the single dominant epitope is the critical region that
determines the epidemiological VE [21–24]. There are five non-
overlapping epitopes on the surface of H3 and H1 HA molecule,
namely epitopes A–E, to which different sets of antibodies bind. In
each epitope, the p value is defined as the fraction of mutated
amino acids [21]. The dominant epitope is defined as the epitope
with the greatest p value. The greatest p value is pepitope [21].
Epidemiological data on the vaccine efficacies in previous flu
seasons when A/H3N2 or A/H1N1 subtype was dominant were
collected [21–24]. The identities of the vaccine strains and
dominant circulating strains were also obtained to calculate pepitope.
The A/H3N2 and A/H1N1 VE correlates with pepitope with
R2=0.81 and R2=0.68, respectively. This correlation shows that
pepitope defined by the single dominant epitope is a quantitative
definition of antigenic distance.
The relation between VE and pepitope is given by E=22.476
pepitope+0.47 (1) for A/H3N2 influenza virus and by E=21.196
pepitope+0.53 (2) for A/H1N1 strains. These two fitted models
predict a vaccine effectiveness of 47% when pepitope=0 for A/
H3N2 and of 53% when pepitope=0 for A/H1N1 [21,23].
The comparison between A/H3N2 and A/H1N1 vaccine effec-
tiveness illustrates that A/H1N1 vaccine has higher effectiveness
than the A/H3N2 vaccine as a function of pepitope. This
observation suggests that the host immune system is more effective
at recognizing and eliminating the A/H1N1 virus (pepitope=0), and
that humoral cross-immunity is stronger for H1 HA (pepitope.0).
By considering only the substitutions that occur in the epitopes,
we calculated the value of the pepitope (as the number of mutations
Figure 1. Weekly influenza epidemic time series. (A). Influenza seasons in Corsica Island. Incidence rate (cases per 100,000 inhabitants) in blue.
In red, the epidemic threshold since 2006–2007 season calculated by a periodic regression model applied to the former observed data (Serfling’s
method). In yellow confidence interval at 95%. (B) Proportions of influenza viruses A/H1N1 pdm; A/H1N1; A/H3N2 and B in Corsica islands.
doi:10.1371/journal.pone.0024471.g001
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acids defining the site), between the influenza virus strains
representatives of the dominant lineage isolated in Corsica Island
with respect to the vaccine strain of each corresponding season.
The antigenic epitope which has the greatest percentage of
mutations was considered as dominant. Percentages of the perfect
match VE were estimated by using the equation 1 and 2 described
precedently.
Results
Prevalence of influenza viruses on Corsica Island from
2006 to 2010
A total of 371 samples were collected and analyzed at the
Sentinelles site on Corsica Island in the four-year period from 2006–
2010. Influenza-like illness activity and the relative prevalence of
influenza virus subtypes from season to season on Corsica Island
are shown in Fig. 1 (A) and (B), respectively.
In 2006–2007 [25], 134 samples were collected from February
2
nd to March 16
th 2007. Out of 134 samples, 93 (69.4%) were
positive and 85 (91.4%) were Influenza type A, whereas influenza
B was detected in 8 (6%) of 93 patients. Of the 85 influenza A
strains identified, 81 (95%) were sub-typed as A/H3N2 and 4 (5%)
were sub-typed as A/H1N1.
In 2007–2008, 85 samples were collected from January 30
th to
February 28
th 2008. Out of 85 samples, 70 (83%) were positive; 61
(87%) were influenza type A and 9 (13%) were typed as influenza
B. Of the 61 influenza A strains identified, 58 (95%) were sub-
typed as A/H1N1 and 3 (5%) were sub-typed as A/H3N2.
In 2008–2009, 98 samples were collected from November 2
nd
2008 to February 18
th 2009. Out of 98 samples, 64 (65%) were
positive; 58 (91%) were Influenza A and 6 (9%) were influenza B.
Of the 58 influenza A strains identified, 100% were sub-typed as
A/H3N2.
In 2009–2010, 54 samples were collected from November 3
rd
2009 to January 11
th 2010. Out of the 54 samples, 33 (61%) were
positive. All positive samples were A/H1N1pdm influenza viruses.
Influenza A/H3N2 viruses
The HA sequences of the A/H3N2 viruses circulating on
Corsica Island during the 2006–2007 (N=16), 2007–2008 (N=2)
and the 2008–2009 seasons (N=45) were compared with the
vaccine strains.
Phylogenetic analysis showed that HA sequences of the A/
H3N2 isolates formed clusters representative for the 2006–2007,
2007–2008 and 2008–2009 seasons.
As previously reported [25], the HA sequences of the A/H3N2
isolated during the 2006–2007 season appeared to be closely
related to the A/Wisconsin/67/2005-like lineage (vaccine strain
for 2006–2007 and 2007–2008 in the Northern Hemisphere)
(Fig. 2). All isolates were characterized by the substitution H156Q
(Fig. 2) with respect to A/Wisconsin/67/2005. Several strains
were characterized by H156Q associated with at least one of these
three additional substitutions: R142G, L157S and K173E (clade I;
Fig. 2).The nucleotide diversity of the A/H3N2 2006–2007
population was 0.00260.001. The nucleotide identities between
the 2006–2007 strains and the A/Wisconsin/67/2005-like lineage
were 99.7% and 99.4% based on amino acids.
The A/H3N2 viruses isolated on Corsica Island during the
2007–2008 season clustered with the A/H3N2 viruses isolated
during the 2006–2007 season and were related to A/Wisconsin/
67/2005. These two strains were not characterized by the
mutation H156Q (Fig. 2; Table 1). The nucleotide identities
between the 2007–2008 strains and the A/Wisconsin/67/2005-
like lineage were 99.6% and 99.4% based on amino acids. The
nucleotide identities between the 2007–2008 strains and the A/
Brisbane/10/2007-like lineage (vaccine strain for the 2008–2009
season in the Northern Hemisphere) were 99.8% and 88.6% based
on amino acids.
The HA sequences of A/H3N2 viruses isolated on Corsica
Island during the 2008–2009 season had drifted from the A/
Wisconsin/67/2005-like lineage (98.1% and 97% similarity based
on nucleotide and amino acids sequences, respectively). These
strains were closely to the A/Brisbane/10/2007-like lineage
(vaccine strain for the 2008–2009 season in the Northern
Hemisphere) (Fig. 2; Table 1). The nucleotide identities between
the 2009 strains and the A/Brisbane/10/2007-like lineage were
99.3% and 98.9% based on amino acids. The nucleotide identities
between the 2009 strains and the A/Perth/16/2009-like lineage
(vaccine strain for the 2009–2010 season in the Northern
Hemisphere) were 98.2% and 96.2% based on amino acids.
The H3 nucleotide sequences of the 2009 virus isolates clustered
into three sub-clades (III, IV and V). All groups were characterized
by two variations (K264P and S265H) compared to the vaccine
strain A/Brisbane/10/2007 (vaccine strain for the 2008–2009
season in the Northern Hemisphere) and by five altered amino
acids (K62E, K144N, N158K, K189N and S214I) with respect to
A/Perth/16/2009 (vaccine strain for the 2009–2010 season in the
Northern Hemisphere). The sub-clade V was characterized by the
supplementary mutation S54N when compared to A/Brisbane/
10/2007 and A/Perth/16/2009 (Fig. 2). The sub-clade III was
characterized by the Q173K mutation with respect to A/Perth/
16/2009. The sub-clade IV showed one supplementary variation
compared to A/Perth/16/2009 (Q173K and L194D). The
K144N mutation was located at antigenic site A, while the
N158K and K189N mutations were located at site B, the S241I
and Q173K mutations were at site D and the K264P and S265H
mutations were at site E.
The nucleotide diversity of this A/H3N2 2008–2009 population
was 0.00560.002. The amino acids at the terminal SA of all H3
isolates were Ile (I)-226 and Ser (S)-228.
Nine potential N-glycosylation sites were predicted in HA1 of
the H3 subtype (8, 22, 38, 63, 126, 133, 165, 246 and 285) with a
threshold .0.5. These sites were found to be conserved in all
isolates obtained during the 2006–2009 seasons. Strains isolated in
2007–2008, 2008–2009 and ten strains (4.2%; 10/42) isolated in
2006–2007 had lost glycosylation at position 144.
Influenza A/H1N1 virus
A/H1N1 isolates from the 2006–2007 (N=1) and 2007–2008
(N=34) season were compared with vaccine strains for phyloge-
netic analysis (Fig. 3; Table 2). The HA sequences of influenza
viruses isolated on Corsica Island during the 2007–2008 season
were separated into two sub-clusters (I and II) as shown in Fig. 3.
Both clades were characterized by the N39D and I189D (antigenic
site B) with respect to A/Brisbane/59/2007 (vaccine strain of the
2008–2009 season in the Northern Hemisphere) (Table 2). Clade
II was characterized by the A62G, S125N (antigenic site B),
W127G, C139S and S140C (antigenic site A), Y209F (at antigenic
site D) and E246Q (Table 2). The isolate A/Corsica/7/2007 was
Figure 2. Phylogenetic tree of the HA domain of the A/H3N2 strains from Corsica Island. Maximum likelihood phylogenetic tree analysis
of HA genes of A/H3N2 strains circulating in Corsica Island from 2006 to 2009 (N represents vaccine strains).
doi:10.1371/journal.pone.0024471.g002
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Amino acid position 50 54 62 122 138 140 144 156 158 173 186 189 194 214 223 264 265
Antigenic sites C AAAABBDBBDD EE
A/Perth/16/2009 E S K N A I K H N Q G K L S V K S
A/Brisbane/10/2007 . . E ...N .K K .N .I...
A/Wisconsin/67/2005 G . E D S K N H K K V N . I I . .
A/Corsica/3/2009 . . E ...N .K ..N .I.P H
A/Corsica/79/2009 . . E ...N .K ..N .I.P H
A/Corsica/85/2009 . . E ...N .K ..N .I.P H
A/Corsica/86/2009 . . E ...N .K K .N P I...
A/Corsica/6/2009 . . E ...N .K ..N .I.P H
A/Corsica/89/2009 . . E ...N .K ..N .I.P H
A/Corsica/83/2009 . . E ...N .K ..N .I.P H
A/Corsica/77/2009 . . E ...N .K ..N .I.P H
A/Corsica/71/2009 . N E ...N .K ..N .I.P H
A/Corsica/72/2009 . . E ...N .K ..N .I.P H
A/Corsica/32/2009 . N E ...N .K ..N .I.P H
A/Corsica/37/2009 . . E ...N .K ..N .I.P H
A/Corsica/42/2009 . N E ...N .K ..N .I.P H
A/Corsica/43/2009 . N E ...N .K ..N .I.P H
A/Corsica/46/2009 . N E ...N .K ..N .I.P H
A/Corsica/31/2009 . N E ...N .K ..N .I.P H
A/Corsica/10/2009 . . E ...N .K ..N .I.P H
A/Corsica/11/2009 . . E ...N .K ..N .I.P H
A/Corsica/12/2009 . . E ...N .K ..N .I.P H
A/Corsica/17/2009 . N E ...N .K ..N .I.P H
A/Corsica/13/2009 . N E ...N .K ..N .I.P H
A/Corsica/14/2009 . . E ...N .K ..N .I.P H
A/Corsica/19/2009 . N E ...N .K ..N .I.P H
A/Corsica/20/2009 . N E ...N .K ..N .I.P H
A/Corsica/22/2009 . N E ...N .K ..N .I.P H
A/Corsica/23/2009 . N E ...N .K ..N .I.P H
A/Corsica/24/2009 . . E ...N .K ..N .I.P H
A/Corsica/25/2009 . . E ...N .K ..N .I.P H
A/Corsica/26/2009 . . E ...N .K ..N .I.P H
A/Corsica/27/2009 . . E ...N .K K .N P I...
A/Corsica/28/2009 . . E ...N .K ..N .I.P H
A/Corsica/29/2009 . . E ...N .K ..N .I.P H
A/Corsica/38/2009 . . E ...N .K ..N .I.P H
A/Corsica/39/2009 . . E ...N .K ..N .I.P H
A/Corsica/65/2009 . . E ...N .K ..N .I.P H
A/Corsica/66/2009 . . E ...N .K ..N .I.P H
A/Corsica/67/2009 . N E ...N .K ..N .I.P H
A/Corsica/68/2009 . N E ...N .K ..N .I.P H
A/Corsica/62/2009 . N E ...N .K ..N .I.P H
A/Corsica/73/2009 . N E ...N .K ..N .I.P H
A/Corsica/81/2009 . N E ...N .K ..N .I.P H
A/Corsica/88/2009 . N E ...N .K ..N .I.P H
A/Corsica/87/2009 . . E ...N .K ..N .I.P H
A/Corsica/80/2009 . . E ...N .K ..N .I.P H
A/Corsica/75/2009 . . E ...N .K ..N .I.P H
A/Corsica/08/2008 G E D S K N K K V N I I
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G240R with respect to A/Brisbane/59/2007 (Fig. 3; Table 2).
The nucleotide identities between the Corsican A/H1N1 2008
strains and the A/Salomon/3/2006-like lineage were 98.9% and
98.7% based on amino acids. The nucleotide identities between
the 2008 strains and the A/Brisbane/59/2007-like lineage were
97.3% and 96.9% based on amino acids.
Seven positions of potential glycosylation with a threshold value
of .0.5 were predicted (at positions 15, 27, 58, 91, 129, 164 and
290). These sites were found to be conserved among all isolates in
this study.
The nucleotide diversity of this the A/H1N1 2008–2009
population was 0.00560.002.
Influenza A/H1N1 pdm virus
The phylogenetic tree of the HA nucleotide sequences of the
Corsican pandemic strains and the vaccine strain is shown in Fig. 4.
The H1 phylogeny showed that the amino acid substitutions P83S
and S203T were found in all of the Corsican isolates. The
substitution D222E was identified in 99% of the A/H1N1pdm
viruses (Table 3). The substitution P83S were assigned to epitope E
and the substitutions S203T and D222E to epitope D. Eight
potential N-glycosylation sites are found in the HA molecule of the
A/California/07/2009 virus,sixofwhichresideintheHA1andthe
remaining in the HA2 region. Four of six potential glycosylation
sites residing in the HA1 region, with a threshold value of .0.5 at
positions 28, 40, 104 and 304, were predicted among the A/
H1N12009 Influenza virus isolated on Corsica Island.
The nucleotide diversity of the A/H1N1pdm isolates in 2009–
2010 was 0.00260.001. The nucleotide identities between the
2009 strains and the A/California/7/2009-like lineage were
99.2% and 99.5% based on amino acids.
Antigenic distance and vaccine efficacy
Vaccine efficacy has a linear correlation with the antigenic
distance between the vaccine strain and the circulating virus
strains [21]. The accumulation of epitope substitutions over time
in influenza viruses strains isolated in Corsica Island are shown in
Fig. 5. We calculated the pepitope antigenic distance between the
2006–2007 vaccine strain A/Wisconsin/67/2005 and the A/
H3N2 Corsican isolates circulating in Corsica Island during 2006–
2007 winter season. The largest pepitope value was 0.095 (epitope B;
substitutions Q156H and L157S), suggesting that two mutations in
dominant epitope B would lead to a rate of worst–case VE against
these strains of 50.1% (E=23.5% of 47%, pepitope=0) of that of a
perfect match between vaccine and virus. We calculated the
antigenic distance from the 2008–2009 vaccine strain A/
Brisbane/10/2007 (H3N2) and the A/H3N2 Corsican strains
isolated in 2008–2009. Using the pepitope method, we found the
largest pepitope value was 0.045 (dominant epitope=E; substitutions
K264P and S265H), suggesting a rate of worst–case VE against
these strains of 76% (E=35.9% of 47%, pepitope=0) of that of a
perfect match (pepitope=0) vaccine.
We calculated the antigenic distance from the 2007–2008
vaccine strain A/Salomon Island/3/2006 (H1N1) and A/H1N1
Corsican strains characterized by the mutation S125N (epitope B).
Using the pepitope method, we found the largest pepitope value was
0.045 (dominant epitope=B), suggesting a rate worst–case VE of
90% (E=47.6% of 53%, pepitope=0) compared of that of a perfect
match (pepitope=0) vaccine.
We calculated the antigenic distance from the vaccine strain of
the Northern Hemisphere in 2009–2010, A/California/7/2009
and the A/H1N1pdm strains having the substitution P83S, S183T
and D222E. The pepitope value was of 0.042 (dominant epitope D),
suggesting a worst–case VE against these strains of 91% (E=48%
of 53%, pepitope=0) of that of a perfect match between vaccine and
virus
Discussion
Genetic and phylogenetic analysis of influenza A viruses
circulating on Corsica Island during the four-year period from
2006–2010 confirmed that the genetic make-up of influenza A
viruses may change from year to year.
Our results showed that the strains of influenza A/(H3N2)
viruses isolated on Corsica Island belonged to two or more
phylogenetic clades co-circulating from the 2006–2007 [25] to
2008–2009 seasons. During the 2006–2007 and 2007–2008
seasons, one clade was dominant. However, in 2006–2007, a
sub-clade of A/Nepal/921/06-like circulating strains accumulated
variations [25], altering their antigenicity as confirmed by HI
assays on representative strains that were conducted by the WHO
Influenza Reference Centre (Mill Hill, London). In 2008–2009,
isolated viruses had drifted from A/Wisconsin/67/2005-like
strains towards the vaccine strain A/Brisbane/10/2007 (vaccine
strain for the 2008–2009 season in the Northern Hemisphere).
These strains showed a higher value of genetic diversity with
respect to the influenza A/H3N2 viruses isolated on Corsica
during the 2006–2007 and 2007–2008 seasons.
Variations in the A/H3N2 viruses isolated on Corsica Island
were predominantly detected at four antigenic sites A, B, D and E
(Table 1). During the 2006–2007 season, a sub-group of isolates
was characterized by four mutations previously described in the
HA1 sequence of the A/Nepal/921/2006 non-vaccine reference
strain and located at antigenic sites A, B and D. Wilson and Cox
[26] have proposed that epidemiologically important drift variants
usually display four or more amino acid substitutions located at
two or more antigenic sites on the HA1 protein. Shih et al. [27]
proposed that new antigenic variants are created when more than
two mutations occur in antigenic sites or when one variation
occurs in one antigenic site and one in a sialic acid RBD. The HA
sequences of A/H3N2 viruses isolated on Corsica Island during
the 2008–2009 season had drifted from the A/Wisconsin/67/
2005-like lineage. These strains, which were characterized by two
fixed mutations located at site E (K264E and K265E) compared to
the vaccine strain A/Brisbane/10/2007, were closely related to
the A/Brisbane/10/2007-like lineage (vaccine strain for the 2008–
2009 season in the Northern Hemisphere). Recently, Huang et al.
[28] showed that a pair of viruses are often ‘‘similar viruses’’ if the
epitope A and B, which are closed to the RBD, are not changed.
Amino acid position 50 54 62 122 138 140 144 156 158 173 186 189 194 214 223 264 265
A/Corsica/10/2008 G E D S K N K K V N I I
doi:10.1371/journal.pone.0024471.t001
Table 1. Cont.
Molecular Characterisation of Influenza A Viruses
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24471Molecular Characterisation of Influenza A Viruses
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24471Few mutations in the A/H1N1 seasonal isolates during the
2007–2008 season that differentiate them from the A/SalomonIs-
lands/3/2006 (S125N at antigenic site B) and A/Brisbane/59/
2007-like (S189D fixed at antigenic site B) lineages were located at
the antigenic sites (Table 2).
These findings seem to indicate that non-synonymous changes
in the HA1 gene, especially in antigenic regions, have been more
frequent in A/H3N2 than in seasonal A/H1N1 in influenza virus
isolated in Corsica Island.
Effectively, since the reintroduction of seasonal A/H1N1 into
human populations in 1977, this subtype has exhibited a lower
case fatality rate than A/H3N2, particularly when these subtypes
co-circulate [29]. In addition, A/H1N1 undergoes less severe
seasonal genetic bottlenecks than A/H3N2, resulting in less
pronounced or frequent reductions in genetic diversity [30].
This hypothesis was supported by subtype-specific differences in
adaptation rate with higher rates of adaptation for A/H3N2 than
A/H1N1 in HA and NA genes [31].
The A/H1N1pdm isolates were characterized by one fixed
mutation at site E and two fixed mutations at site D with respect to
A/California/07/2009 (Table 3). All Corsican A/H1N1pdm
strains analyzed were characterized by the S203T mutation
specific to clade 7 isolates [32]. The clade 7 marker variation
S203T, observed in all sampled Corsican viruses, is a A/
H1N1pdm virus site under positive selection and also involved
in antigenicity [33].
The viruses constituting this clade were therefore responsible for
most of the pandemic burden worldwide. Following its origin,
which remains obscure, the clade 7 viruses have been subjected to
strong purifying selection, with the exception of the earliest phases
of its evolution, behaving later as a well-fit virus, similar to viruses
circulating in swine or seasonal influenza in humans.
Overrepresentation of certain mutations among geographically
and temporally related samples needs to be carefully controlled for
possible founder effects which could be identified as homogenous
clusters in phylogenetic analyses, as was observed to be the case for
the D222E mutation. Phylogenetic analysis of A/H1N1pdm
influenza viruses showed that viruses isolated in Corsica Island
formed a separate sub-clade of clade 7 as a consequence of the
presence of the D222E substitution. While founder effect
mutations cannot automatically be linked to phenotypes simply
by increased occurrence, they may nevertheless alter the virus
fitness for which even tiny changes could result in advantages
shifting selection to their favor [34]. Recent studies showed that
this position was positively selected for human strains [35–36].
Moreover, this codon, located in antigenic site D, is also associated
with RBD indicating a positive selection from the hosts, caused
maybe by vaccination and mass use of antiviral drugs.
This mutation, whose biological meaning is still unknown, has
been isolated in other countries but at lower frequencies (e.g.; Italy,
Turkey, Sweden and Finland). Recently, a cluster of D222E
viruses among school children was isolated in Italy, confirming
human-to-human transmission of viruses mutated at amino acid
position 222 [37].
The D222G mutation was not observed among A/H1N1pdm
isolated on Corsica Island. This substitution was observed more
frequently in viruses isolated from patients with fatal outcomes
[38].
Several studies showed that the A/H1N1pdm virus has a high
genome-wide evolutionary rate (3.6661023 substitutions/site/
year) [39] and a rate for the HA segment (0.961023 substitu-
tions/site/year) that represents the lowest of all of the viral HAs of
seasonal A/H1N1 (1918–1957; 2.961023), seasonal A/H1N1
(1977–2009; 1.761023), and swine H1 (1930–2009; 1.961023)
[33].
Figure 3. Phylogenetic tree of the HA domain of the A/H1N1 strains from Corsica Island. Maximum likelihood phylogenetic tree analysis
of HA genes of A/H1N1 strains circulating in Corsica Island during 2007–2008 season (N represents vaccine strains).
doi:10.1371/journal.pone.0024471.g003
Table 2. Amino acid substitution in A/H1N1 influenza viruses
isolated in Corsica Island from 2007 to 2008.
Amino acid positions 39 62 125 127 139 140 189 209 240 246
Antigenic sites B A B D D
A/Brisbane/59/2007 N A S W C S I Y G E
A/SalomonIslands
/3/2006
DAS WC S D Y G E
A/Corsica/30/2008 D G ....D ..Q
A/Corsica/51/2008 D . ....D ...
A/Corsica/75/2008 D . N . . . D . . .
A/Corsica/4/2008 D G . G . . D F . .
A/Corsica/17/2008 D G . G . . D . . .
A/Corsica/29/2008 D G . G S C D . .
A/Corsica/34/2008 D G N . . . D . . .
A/Corsica/69/2008 D . N . . . D . . .
A/Corsica/15/2008 D G ....D ..Q
A/Corsica/13/2008 D . ....D ...
A/Corsica/12/2008 D . N . . . D . . .
A/Corsica/6/2008 D G . G S C D . .
A/Corsica/3/2008 D G N . . . D . .
A/Corsica/47/2008 D . N . . . D . . .
A/Corsica/41/2008 D G ....D ..Q
A/Corsica/52/2008 D . ....D ...
A/Corsica/76/2008 D . N . . . D . . .
A/Corsica/1/2008 D G . G . . D F . .
A/Corsica/25/2008 D G ....D ..Q
A/Corsica/27/2008 D . N . . . D . . .
A/Corsica/13/2008 D G . G S C D . .
A/Corsica/26/2008 D . ....D ...
A/Corsica/39/2008 D G N . . . D . .
A/Corsica/40/2008 D . N . . . D . . .
A/Corsica/44/2008 D G ....D ..Q
A/Corsica/22/2008 D . ....D ...
A/Corsica/11/2008 D . N . . . D . . .
A/Corsica/64/2008 D G . G . . D F . .
A/Corsica/66/2008 D . N . . . D . . .
A/Corsica/72/2008 D G ....D ..Q
A/Corsica/80/2008 D . ....D ...
A/Corsica/45/2008 D G ....D ..Q
A/Corsica/33/2008 D . ....D ...
A/Corsica/48/2008 D . N . . . D . . .
A/Corsica/7/2007 . . ....D .R .
doi:10.1371/journal.pone.0024471.t002
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24471All Corsican A/H1N1pdm isolates possessed D204 in the RBD,
which confers binding of H1 viruses to human receptors,
supporting efficient transmission of these viruses in humans. Key
residues in the RBD [40] predicted to have a role in binding to
human receptors (T98Y, S136T, 153W and 183H) were found to
be Y98, S136, W153 and H183 in the Corsican isolates as in other
A/H1N1pdm viruses isolated elsewhere.
Among the A/H3N2 Corsican isolates, the residues mainly for
NeuAca2,6Gal linkage specific for the H3 subtype were Ile(I)226
and Ser (S)228, similar to other studies [41].
N-linked glycosylation is conserved among various HA subtypes
of influenza A viruses. Its presence or absence can cause an
increase or loss in function of the glycoprotein because N-linked
glycosylation can initiate and maintain folding, stability, solubility,
antigenicity and immunogenicity of the protein. Most of the
currently circulating viruses have six or seven N- glycosylation sites
in the HA globular head region. Interestingly, the predicted N-
linked glycosylation site at position 144 of the HA antigenic site A
has been observed in the majority of strains isolated on Corsica in
2006–2007 and was definitively lost during the 2007–2008 and
2008–2009 seasons. Other studies have reported the loss of this
predicted N-linked glycosylation site in all strains isolated since
2006–2007 [42].
In this study, we tried to predict a rate of VE for A/H3N2 and
A/H1N1 seasonal influenza viruses and of the A/H1N1pdm virus
using the pepitope model. This model has been developed to provide
researchers and health authorities with a new tool to quantify
antigenic distance and to help with vaccine design. These results
showed that the rate of VE compared to that of a perfect match
against influenza viruses circulating on Corsica Island varied
substantially across the four seasons analyzed, and that tend to be
highest for A/H1N1 compared with A/H3N2 vaccines, suggesting
that cross-immunity seems to be stronger for H1 HA gene [23].
Even if, as precedently described [21], the vaccine effectiveness
estimated by several epidemiologic studies seems to be supported
by the pepitope model, the rate of VE estimated in this study need to
be boosted with real VE data from the same patients.
Nevertheless, studying the relationship between epitopes and
vaccine efficiency [21] could be useful for studying influenza virus
evolution and to consolidate studies based on epidemiological
data.
One important limit of this study is that we have not analyzed
the genetic evolution of the influenza virus outside HA proteins.
Suzuki (2008) [43] applied a dN/dS approach to 100 complete
H3N2 genomes and concluded that negative selection dominated
in all proteins; significant positive selection was observed only in a
handful of codons in the HA, NA and NP genes. Pond et al.,
(2008) [44] analyzed the same data using a technique more
sensitive to the detection of individual selective sweeps and
reported more evidence for adaptation in 5 genes: PB2 (2 codons),
PB1 (5 codons), PA (3 codons), HA (81 codons), and NA (4
codons).
A recent study [31] showed that the rate of adaptation (per
codon per year) is higher in surface residues of the viral NA than in
HA1, indicating strong antibody-mediated selection on the former.
They also observed high rates of adaptive evolution in several non-
structural proteins, which may relate to viral evasion of T-cells and
innate immune responses [31].
Another limit of the study is based on the sensitivity and
specificity of molecular techniques used to identify strains and on
the quality of specimens analyzed. Even if, the M RT-PCR used in
this study to identify influenza A virus is specific and sensitive,
there is a limit of detection between 10 and 100 copies/reaction
[15].
The molecular analysis of the HA gene of influenza viruses that
circulated on Corsica Island between 2006–2010 showed for each
season the presence of a dominant lineage characterized by at least
one fixed mutation. It must be noted that A/H3N2 and A/
H1N1pdm were characterized by multiples fixation at antigenic
sites. Subsequent mutations at antigenic sites often significantly
contribute additional effects, so that multiple fixations, possibly
including hitchhikers, occur rapidly and (almost) simultaneously.
The fixation of specific mutations at each outbreak could be
Figure 4. Phylogenetic tree of the HA domain of the A/H1N1 pdm strains from Corsica Island. Maximum likelihood phylogenetic tree
analysis of HA genes of A/H1N1 strains circulating in Corsica Island during 2009–2010 season (N represents vaccine strains).
doi:10.1371/journal.pone.0024471.g004
Table 3. Amino acid substitution in A/H1N1 pdm influenza
viruses isolated in Corsica Island during 2009–2010.
Amino acid position 32 83 203 222
Antigenic sites ED D
A/California/07/2009 L P S D
A/Corsica/01/2009 . S T E
A/Corsica/02/2009 . S T E
A/Corsica/03/2009 . S T E
A/Corsica/04/2009 . S T E
A/Corsica/05/2009 . S T E
A/Corsica/08/2009 . S T E
A/Corsica/09/2009 . S T E
A/Corsica/10/2009 . S T E
A/Corsica/11/2009 I S T
A/Corsica/15/2009 . S T E
A/Corsica/16/2009 . S T E
A/Corsica/18/2009 . S T E
A/Corsica/19/2009 . S T E
A/Corsica/20/2009 . S T E
A/Corsica/22/2009 . S T E
A/Corsica/23/2009 . S T E
A/Corsica/24/2009 . S T E
A/Corsica/25/2009 . S T E
A/Corsica/27/2009 . S T E
A/Corsica/28/2009 . S T E
A/Corsica/36/2009 . S T E
A/Corsica/38/2009 . S T E
A/Corsica/39/2009 . S T E
A/Corsica/40/2009 . S T E
A/Corsica/42/2009 . S T E
A/Corsica/45/2009 . S T E
A/Corsica/48/2009 . S T E
A/Corsica/49/2009 . S T E
A/Corsica/50/2009 . S T E
A/Corsica/52/2009 . S T E
doi:10.1371/journal.pone.0024471.t003
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PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24471explained by the combination of compensatory mutations, neutral
phenomenon and a founder effect, favoring the presence of a
dominant lineage in a closed environment such as Corsica Island.
These findings confirmed that careful surveillance of genetic changes
in the HA1 domain during the influenza epidemic season may provide
early information on virus variants and improve the influenza vaccine.
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